Inmed pharmaceuticals files pct patent application for treating neurodegenerative disease using a rare cannabinoid

Vancouver, british columbia, nov. 03, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announced that it has filed an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potential treatment of neurodegenerative diseases such as alzheimer's disease, parkinson's disease, huntington's disease and others.
INM Ratings Summary
INM Quant Ranking